High Plasma Concentration of Apolipoprotein C-III Confers an Increased Risk of Cerebral Ischemic Events on Cardiovascular Patients Anticoagulated With Warfarin.

Journal: Frontiers in cardiovascular medicine
Published Date: Feb 4, 2022

Abstract

INTRODUCTION: Apolipoprotein C-III (Apo CIII) is a crucial regulator of triglyceride-rich lipoproteins (TRLs) and influences the risk of cardiovascular diseases. High levels of Apo CIII have been also associated with cerebrovascular events and earlier works showed procoagulant effects of Apo CIII. The main aim was to assess whether the plasma concentration of Apo CIII could confer an increased risk of cerebral ischemic events in anticoagulated patients at high-risk of cardioembolism.

Authors

  • Oliviero Olivieri
    Unit of Internal Medicine, Department of Medicine, University of Verona, Verona, Italy.
  • Gianni Turcato
    Department of Emergency Medicine, Franz Tappeiner Hospital, Merano, Italy.
  • Manuel Cappellari
    Stroke Unit, Borgo Trento Hospital, Verona, Italy.
  • Filippo Stefanoni
    Unit of Internal Medicine, Department of Medicine, University of Verona, Verona, Italy.
  • Nicola Osti
    Unit of Internal Medicine, Department of Medicine, University of Verona, Verona, Italy.
  • Francesca Pizzolo
    Unit of Internal Medicine, Department of Medicine, University of Verona, Verona, Italy.
  • Simonetta Friso
    Unit of Internal Medicine, Department of Medicine, University of Verona, Verona, Italy.
  • Antonella Bassi
    Laboratory of Clinical Chemistry and Hematology, University Hospital of Verona, Verona, Italy.
  • Annalisa Castagna
    Unit of Internal Medicine, Department of Medicine, University of Verona, Verona, Italy.
  • Nicola Martinelli
    Unit of Internal Medicine, Department of Medicine, University of Verona, Verona, Italy.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals